Segments of Business and Geographic Areas (Details 1) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges				$ 185	$ 1,034
Restructuring charges		$ 114	$ 0	$ 234	0
Percentage Change in Operating Income Loss		(14.60%)		(9.90%)
Earnings before provision for taxes on income		$ 4,904	5,741	$ 10,198	11,316
Pharmaceutical
Segment Reporting Information [Line Items]
Valuation Allowances and Reserves, Adjustments		342	199	539	403
Gain (Loss) on Sale of Assets and Asset Impairment Charges			981		981
Litigation Expense					136
Medical Devices
Segment Reporting Information [Line Items]
Litigation Expense		570	134	676
Restructuring charges		141		278
Litigation Settlement, Amount					404
Product Liability Accrual, Period Expense					148
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 5,197	6,023	$ 10,683	11,850
Percentage Change in Operating Income Loss		(13.70%)		(9.80%)
Operating Segments [Member] | Consumer
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 571	317	$ 1,137	961
Percentage Change in Operating Income Loss		80.10%		18.30%
Operating Segments [Member] | Pharmaceutical
Segment Reporting Information [Line Items]
Total Segment Operating Income	[1]	$ 3,687	4,122	$ 7,031	7,084
Percentage Change in Operating Income Loss		(10.60%)		(0.70%)
Operating Segments [Member] | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	[2]	$ 939	1,584	$ 2,515	3,805
Percentage Change in Operating Income Loss		(40.70%)		(33.90%)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	[3]	$ 293	$ 282	$ 485	$ 534

[1] Includes litigation expense of $136 million recorded in the fiscal six months of 2015. Includes a gain of $981 million recorded in the fiscal second quarter and first fiscal six months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes a positive adjustment of $539 million and $403 million to previous reserve estimates in the fiscal six months of 2016 and 2015, respectively. Includes a positive adjustment of $342 million and $199 million to previous reserve estimates in the fiscal second quarter of 2016 and 2015, respectively.

[2] Includes a restructuring charge of $141 million and $278 million in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $570 million and $676 million recorded in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $134 million in the fiscal second quarter of 2015 and a net litigation gain of $404 million primarily related to a litigation settlement agreement with Guidant recorded in the fiscal six months of 2015. The fiscal six months of 2015 included $148 million for costs associated with the DePuy ASRTM Hip program.

[3] Amounts not allocated to segments include interest income/expense and general corporate income/expense.